Fertil Steril:控制子宫内膜异位症相关疼痛:ENG避孕植入剂vs LNG-IUS

2018-11-20 吴星 环球医学网

2018年11月,发表于《Fertil Steril》上的一项随机临床试验,考察了依托孕烯(ENG)避孕植入剂和左炔诺孕酮52 mg宫内节育系统(LNG-IUS),控制子宫内膜异位症相关疼痛的效果。

2018年11月,发表于《Fertil Steril》上的一项随机临床试验,考察了依托孕烯(ENG)避孕植入剂和左炔诺孕酮52 mg宫内节育系统(LNG-IUS),控制子宫内膜异位症相关疼痛的效果。

目的:评价ENG避孕植入剂或LNG-IUS控制子宫内膜异位症相关盆腔疼痛的效果。

设计:非劣效性随机临床试验,将纳入的子宫内膜异位症女性分配至使用ENG植入组(试验组)或LNG-IUS(阳性对照组)。每月进行随访,直至6个月。

地点:大学教学医院。

受试者:103例子宫内膜异位症相关的慢性盆腔疼痛、痛经或二者兼有的患者,且疼痛持续6个月以上。对于深部子宫内膜异位症患者,使用阴道超声和核磁共振(MRI)作为额外的诊断工具。

干预:在月经周期的前5天内,使用ENG植入剂或LNG-IUS。

主要结局和测量指标:使用每日视觉模拟评分量表,对每天的非周期性盆腔痛和痛经进行评分。使用子宫内膜异位症健康-30调查问卷,在基线和6个月内评价受试者健康相关生活质量。根据月经日历每日评估出血模式。

结果:两种避孕方法均显着改善子宫内膜异位症相关盆腔疼痛的视觉模拟评分和痛经,两组间没有显着差异。子宫内膜异位症健康-30调查问卷核心模块所有领域的健康相关生活质量均得到改善,两组间无显着差异。随访180天,ENG植入剂和LNG-IUS使用者的最常见的出血方式分别为闭经(28.8%)和经常出血(24.4%),不经常出血(30%)和点状出血(22.1%)。

结论:在这项非劣效性研究中,两种避孕方法均显着改善子宫内膜异位症相关盆腔疼痛、痛经,以及健康相关生活质量。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2081506, encodeId=2d5d2081506e9, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Tue Nov 27 15:32:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708489, encodeId=67b11e0848962, content=<a href='/topic/show?id=4c2d3051535' target=_blank style='color:#2F92EE;'>#内膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30515, encryptionId=4c2d3051535, topicName=内膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730431558473, createdName=12498974m61暂无昵称, createdTime=Sat Mar 02 20:32:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665641, encodeId=43e916656418c, content=<a href='/topic/show?id=685445152f6' target=_blank style='color:#2F92EE;'>#子宫内膜异位#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45152, encryptionId=685445152f6, topicName=子宫内膜异位)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4de125981980, createdName=12498f17m74暂无昵称, createdTime=Sun Jan 27 00:32:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520526, encodeId=629315205264b, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Thu Nov 22 10:32:00 CST 2018, time=2018-11-22, status=1, ipAttribution=)]
    2018-11-27 spoonycyy
  2. [GetPortalCommentsPageByObjectIdResponse(id=2081506, encodeId=2d5d2081506e9, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Tue Nov 27 15:32:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708489, encodeId=67b11e0848962, content=<a href='/topic/show?id=4c2d3051535' target=_blank style='color:#2F92EE;'>#内膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30515, encryptionId=4c2d3051535, topicName=内膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730431558473, createdName=12498974m61暂无昵称, createdTime=Sat Mar 02 20:32:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665641, encodeId=43e916656418c, content=<a href='/topic/show?id=685445152f6' target=_blank style='color:#2F92EE;'>#子宫内膜异位#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45152, encryptionId=685445152f6, topicName=子宫内膜异位)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4de125981980, createdName=12498f17m74暂无昵称, createdTime=Sun Jan 27 00:32:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520526, encodeId=629315205264b, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Thu Nov 22 10:32:00 CST 2018, time=2018-11-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2081506, encodeId=2d5d2081506e9, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Tue Nov 27 15:32:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708489, encodeId=67b11e0848962, content=<a href='/topic/show?id=4c2d3051535' target=_blank style='color:#2F92EE;'>#内膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30515, encryptionId=4c2d3051535, topicName=内膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730431558473, createdName=12498974m61暂无昵称, createdTime=Sat Mar 02 20:32:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665641, encodeId=43e916656418c, content=<a href='/topic/show?id=685445152f6' target=_blank style='color:#2F92EE;'>#子宫内膜异位#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45152, encryptionId=685445152f6, topicName=子宫内膜异位)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4de125981980, createdName=12498f17m74暂无昵称, createdTime=Sun Jan 27 00:32:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520526, encodeId=629315205264b, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Thu Nov 22 10:32:00 CST 2018, time=2018-11-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2081506, encodeId=2d5d2081506e9, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Tue Nov 27 15:32:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708489, encodeId=67b11e0848962, content=<a href='/topic/show?id=4c2d3051535' target=_blank style='color:#2F92EE;'>#内膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30515, encryptionId=4c2d3051535, topicName=内膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730431558473, createdName=12498974m61暂无昵称, createdTime=Sat Mar 02 20:32:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665641, encodeId=43e916656418c, content=<a href='/topic/show?id=685445152f6' target=_blank style='color:#2F92EE;'>#子宫内膜异位#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45152, encryptionId=685445152f6, topicName=子宫内膜异位)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4de125981980, createdName=12498f17m74暂无昵称, createdTime=Sun Jan 27 00:32:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520526, encodeId=629315205264b, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Thu Nov 22 10:32:00 CST 2018, time=2018-11-22, status=1, ipAttribution=)]
    2018-11-22 jiyangfei

相关资讯

ICER最终报告:Elagolix对子宫内膜异位症的长期安全性和有效性

临床和经济评论研究所(ICER)近日发布了一份关于elagolix(Orilissa,AbbVie)的最终证据报告,近期,elagolix已被FDA批准用于治疗与子宫内膜异位症相关的中度至重度疼痛。

2018 KSE指南:子宫内膜异位症的临床评估和管理

2018年9月,韩国子宫内膜异位症学会(KSE)发布了子宫内膜异位症的临床评估和管理指南,子宫内膜异位症是育龄期女性最常见的疾病之一,严重影像了患者的生活质量以及生育能力。本文主要针对子宫内膜异位症的临床评估和管理提供指导建议。

Cell Death Dis:研究揭示人参皂甙治疗子宫内膜异位症的作用机制

子宫内膜异位症(EMS)是一种雌激素依赖性女性疾病,具有低自噬水平的异位子宫内膜基质细胞(eESCs)。受损的NK细胞细胞毒性活性涉及腹盆腔内异位内膜组织的清除障碍。原人参二醇(PPD)和原人参三醇(PPT)是人参皂甙的两种代谢物,具有多种生物学功能,如抗癌活性。然而,人参皂甙和代谢产物在子宫内膜异位症中的作用和机制是完全未知的。 本研究中,研究人员发现化合物PPD、PPT、人参皂苷-Rg3

FDA批准**口服促性腺激素释放激素拮抗剂用于治疗子宫内膜异位症

AbbVie和Neurocrine近日宣布美国FDA批准Orilissa作为首个也是唯一一个口服促性腺激素释放激素(GnRH)拮抗剂,专门用于治疗患有中度至重度子宫内膜异位症疼痛的女性患者。

2018 CNGOF/HAS临床实践指南:子宫内膜异位症的管理

2018年6月,法国国家妇产科医生协会(CNGOF)发布了子宫内膜异位症的管理指南,本文是对2006版法国子宫内膜异位症的管理指南的更新,指南主要内容涉及腹膜,卵巢以及深层子宫内膜异位症的诊断和管理。

Am J Obstet Gynecol:女人不能做肉食动物 否则子宫内膜异位症风险来报复

子宫内膜异位症是一种良性的雌激素依赖性妇科疾病,育龄女性的患病率约为10%。其病因尚未完全知晓。饮食或可通过影响甾体激素,从而影响子宫内膜异位症的发生风险。例如,红肉可降低性激素结合球蛋白(SHBG)并增加雌二醇浓度。